Collected : 01/Oct/2020 12:40PM
Patient Name : Mrs.SUJATHA
Received : 01/Oct/2020 02:38PM
Age/Gender : 68 Y 0 M 0 D /F
Reported : 01/Oct/2020 03:23PM
UHID/MR No : DAPK.0000042426
Status : Final Report
Visit ID : DCPTOPV4113
Client Name : PCC CHROMPET
Ref Doctor : Dr.SELF
: 2nd Block Mogapper West
IP/OP NO : Patient location
Street,Chennai
DEPARTMENT OF BIOCHEMISTRY
CAMPAIGN DIABETIC CHECK ( WITH PP )
Test Name Result Unit Bio. Ref. Range Method
GLUCOSE, FASTING , NAF PLASMA 125 mg/dL 70 - 100 GOD - POD
GLUCOSE, POST PRANDIAL (PP), 2 247 mg/dL 70 - 140 GOD - POD
HOURS , NAF PLASMA
Comment:
It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each
other.
Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive
hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin
preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.
Ref: Marks medical biochemistry and clinical approach
Page 1 of 2
Collected : 01/Oct/2020 12:40PM
Patient Name : Mrs.SUJATHA
Received : 01/Oct/2020 02:38PM
Age/Gender : 68 Y 0 M 0 D /F
Reported : 01/Oct/2020 03:23PM
UHID/MR No : DAPK.0000042426
Status : Final Report
Visit ID : DCPTOPV4113
Client Name : PCC CHROMPET
Ref Doctor : Dr.SELF
: 2nd Block Mogapper West
IP/OP NO : Patient location
Street,Chennai
DEPARTMENT OF BIOCHEMISTRY
CAMPAIGN DIABETIC CHECK ( WITH PP )
Test Name Result Unit Bio. Ref. Range Method
HBA1C, GLYCATED HEMOGLOBIN , WHOLE 10.6 % HPLC
BLOOD-EDTA
ESTIMATED AVERAGE GLUCOSE (eAG) , 258 mg/dL Calculated
WHOLE BLOOD-EDTA
Comment:
Reference Range as per American Diabetes Association (ADA):
REFERENCE GROUP HBA1C IN %
NON DIABETIC ADULTS >18 YEARS <5.7
AT RISK (PREDIABETES) 5.7 – 6.4
DIAGNOSING DIABETES >= 6.5
DIABETICS
· EXCELLENT CONTROL 6 – 7
· FAIR TO GOOD CONTROL 7 – 8
· UNSATISFACTORY CONTROL 8 – 10
· POOR CONTROL >10
Note: Dietary preparation or fasting is not required.
1. A1C test should be performed at least two times a year in patients who are meeting treatment goals (and who have stable
glycemic control).
2. Lowering A1C to below or around 7% has been shown to reduce microvascular and neuropathic complications of type 1
and type 2 diabetes. When mean annual HbA1c is <1.1 times ULN (upper limit of normal), renal and retinal complications
are rare, but complications occur in >70% of cases when HbA1c is >1.7 times ULN.
3. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or
decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect
erythrocyte survival are present. Fructosamine may be used as an alternate measurement of glycemic control
*** End Of Report ***
Result/s to Follow:
CREATININE, SERUM, C-REACTIVE PROTEIN CRP (QUANTITATIVE), DENGUE PROFILE (IGG & IGM ANTIBODY & NS1 ANTIGEN) BY ELISA
Page 2 of 2
SIN No:BI04802577,BI04802578,BI04802579
This test has been performed at Apollo Health and Lifestyle Ltd - Chennai, Diagnostics Laboratory.